Fellow Seeking Alpha contributor Paul Nouri made a very solid call naming Trinity Biotech (TRIB)
a Top Idea back in late June, as the shares have risen about 60% since
then. While I do like this under-followed Irish diagnostics specialist, I
have to wonder if the stock has gone too far too fast. Even if I assume
uncommonly high free cash flow margins and that the company captures
one-third of the troponin and BNP testing markets, the numbers just
don't work for me right now.
Please read more here:
Trinity Biotech Getting A Head-Of-The-Class Multiple
No comments:
Post a Comment